Search Results - ca2cxx

3 Results

Sort By:

Boron Amino Acid Mimetics for PET Imaging of Cancer

Available for licensing and commercial development as imaging agents for positron emission tomography of cancer are boramino acid compounds. The inventors showed that mimetics created by substituting the carboxylate group (-COO-) of an amino acid with trifluoroborate (-BF3-) are metabolically stable and allow for the use of fluorene-18 (18F) as the...

Published: 7/25/2024 | Inventor(s): Zhibo Liu, Xiaoyuan (Shawn) Chen

Keywords(s): AA3CXX, Boramino, CA1CXX, CA2BXX, CA2CXX, Cancer diagnosis, Cancer diagnostic, fluorene-18, Mimetic, MIMETICS, positron emission, VCXXXX, WBXXXX, WIXXXX, XFXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Research Materials, Application > Medical Devices, Application > Diagnostics, Application > Non-Medical Devices, Application > Software / Apps, TherapeuticArea > Oncology

Octopod (8-Pointed Star) Iron Oxide Nanoparticles Enhance MRI T2 Contrast

The octopod-shaped iron oxide nanoparticles of this technology significantly enhance contrast in MRI imaging compared to spherical superparamagnetic iron oxide nanoparticle T2 contrast agents. These octopod iron oxide nanoparticles show a transverse relaxivity that is over five times greater than comparable spherical agents. Because the unique octopod...

Published: 7/25/2024 | Inventor(s): Jinhao Gao, Zhenghuan Zhao, Xiaoyuan (Shawn) Chen

Keywords(s): Agents, CA2CXX, Contrast, High-Performance, IMAGING, IRON, Magnetic, Nanoparticles, Non-spherical, OXIDE, PXXXXX, Resonance, T2, VCXXXX, VDXXXX, WBXXXX, XFXXXX, XGXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, TherapeuticArea > Cardiology, Application > Therapeutics, Application > Consumer Products, TherapeuticArea > Oncology, Application > Software / Apps, Application > Non-Medical Devices, Application > Medical Devices

Agonist Epitopes for Renal Cell Carcinoma

Approximately 30,000 patients are diagnosed with renal cell carcinoma (RCC) each year in the United States, and an estimated 12,000 patients die of this disease. Most patients are diagnosed with advanced local disease or metastatic disease. Metastatic RCC carries a poor prognosis with median survivals in the range of 10-12 months. Drugs that inhibit...

Published: 7/25/2024 | Inventor(s): Richard Childs

Keywords(s): BBXXXX, CA1AXX, CA1XXX, CA2CXX, CA2XXX, Carcinoma, CAXXXX, CB2BXX, CB2XXX, CB4XXX, CBXXXX, Cell, Cells, CXXXXX, Discovery, Expression, Gene, Kidney cancer, adult, Patent Category - Biotechnology, previously, RDD, RENAL, Renal cell carcinoma 1, Renal cell carcinoma 4, Restricted, Uncharacterized, WHOSE

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Oncology